Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications
The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell res...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sergey G. Sсherbak [verfasserIn] Dmitry A. Vologzhanin [verfasserIn] Aleksandr S. Golota [verfasserIn] Tatyana A. Kamilova [verfasserIn] Stanislav V. Makarenko [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Клиническая практика - Eco-vector, 2020, 13(2022), 2, Seite 66-87 |
|---|---|
| Übergeordnetes Werk: |
volume:13 ; year:2022 ; number:2 ; pages:66-87 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.17816/clinpract106239 |
|---|
| Katalog-ID: |
DOAJ039825175 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ039825175 | ||
| 003 | DE-627 | ||
| 005 | 20230308032742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17816/clinpract106239 |2 doi | |
| 035 | |a (DE-627)DOAJ039825175 | ||
| 035 | |a (DE-599)DOAJ39ba1e87f8294120b3e9075132952fc1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a Sergey G. Sсherbak |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell response that forms a basis for an effective neutralizing antibody response. T cell responses develop early and correlate with the protection, but they are relatively attenuated in the severe disease, in part due to lymphopenia. Understanding the role of different T cell subpopulations in the protection or the COVID-19 pathogenesis is critical to the prevention and treatment. The expression profile of different T cell subpopulations varies with the COVID-19 severity and is associated with the degree of T cell responses and the disease outcome. The structural changes in the genome, transcriptome, and proteome of SARS-CoV-2 promote the emergence of new variants of the virus and can reduce its interaction with antibodies and result in avoiding the neutralization. There is a strong correlation between the number of virus-specific CD4 T cells and neutralizing IgG antibody titers against SARS-CoV-2. During the primary viral infection, there is a wide variation in the cellular and humoral immune responses, patients with severe and prolonged symptoms showing highly imbalanced cellular and humoral immune responses. This review focuses on the generation and clinical significance of cellular immunity in the protection against severe acute infection and reinfection, as well as the potential involvement of seasonal coronavirus-specific cross-reactive T cells in response to SARS-CoV-2. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a sars-cov-2 coronavirus | |
| 650 | 4 | |a cellular immunity | |
| 650 | 4 | |a immunological memory | |
| 650 | 4 | |a neutralizing antibodies | |
| 650 | 4 | |a cross-reactive immunity | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Dmitry A. Vologzhanin |e verfasserin |4 aut | |
| 700 | 0 | |a Aleksandr S. Golota |e verfasserin |4 aut | |
| 700 | 0 | |a Tatyana A. Kamilova |e verfasserin |4 aut | |
| 700 | 0 | |a Stanislav V. Makarenko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Клиническая практика |d Eco-vector, 2020 |g 13(2022), 2, Seite 66-87 |w (DE-627)DOAJ078636620 |x 26188627 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:2 |g pages:66-87 |
| 856 | 4 | 0 | |u https://doi.org/10.17816/clinpract106239 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/39ba1e87f8294120b3e9075132952fc1 |z kostenfrei |
| 856 | 4 | 0 | |u https://journals.eco-vector.com/clinpractice/article/viewFile/106239/pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2220-3095 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2618-8627 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 2 |h 66-87 | ||
| author_variant |
s g s sgs d a v dav a s g asg t a k tak s v m svm |
|---|---|
| matchkey_str |
article:26188627:2022----::ellrmuiynainsihoi1mlclrilgptohsoo |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.17816/clinpract106239 doi (DE-627)DOAJ039825175 (DE-599)DOAJ39ba1e87f8294120b3e9075132952fc1 DE-627 ger DE-627 rakwb rus Sergey G. Sсherbak verfasserin aut Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell response that forms a basis for an effective neutralizing antibody response. T cell responses develop early and correlate with the protection, but they are relatively attenuated in the severe disease, in part due to lymphopenia. Understanding the role of different T cell subpopulations in the protection or the COVID-19 pathogenesis is critical to the prevention and treatment. The expression profile of different T cell subpopulations varies with the COVID-19 severity and is associated with the degree of T cell responses and the disease outcome. The structural changes in the genome, transcriptome, and proteome of SARS-CoV-2 promote the emergence of new variants of the virus and can reduce its interaction with antibodies and result in avoiding the neutralization. There is a strong correlation between the number of virus-specific CD4 T cells and neutralizing IgG antibody titers against SARS-CoV-2. During the primary viral infection, there is a wide variation in the cellular and humoral immune responses, patients with severe and prolonged symptoms showing highly imbalanced cellular and humoral immune responses. This review focuses on the generation and clinical significance of cellular immunity in the protection against severe acute infection and reinfection, as well as the potential involvement of seasonal coronavirus-specific cross-reactive T cells in response to SARS-CoV-2. covid-19 sars-cov-2 coronavirus cellular immunity immunological memory neutralizing antibodies cross-reactive immunity Medicine R Dmitry A. Vologzhanin verfasserin aut Aleksandr S. Golota verfasserin aut Tatyana A. Kamilova verfasserin aut Stanislav V. Makarenko verfasserin aut In Клиническая практика Eco-vector, 2020 13(2022), 2, Seite 66-87 (DE-627)DOAJ078636620 26188627 nnns volume:13 year:2022 number:2 pages:66-87 https://doi.org/10.17816/clinpract106239 kostenfrei https://doaj.org/article/39ba1e87f8294120b3e9075132952fc1 kostenfrei https://journals.eco-vector.com/clinpractice/article/viewFile/106239/pdf kostenfrei https://doaj.org/toc/2220-3095 Journal toc kostenfrei https://doaj.org/toc/2618-8627 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 13 2022 2 66-87 |
| spelling |
10.17816/clinpract106239 doi (DE-627)DOAJ039825175 (DE-599)DOAJ39ba1e87f8294120b3e9075132952fc1 DE-627 ger DE-627 rakwb rus Sergey G. Sсherbak verfasserin aut Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell response that forms a basis for an effective neutralizing antibody response. T cell responses develop early and correlate with the protection, but they are relatively attenuated in the severe disease, in part due to lymphopenia. Understanding the role of different T cell subpopulations in the protection or the COVID-19 pathogenesis is critical to the prevention and treatment. The expression profile of different T cell subpopulations varies with the COVID-19 severity and is associated with the degree of T cell responses and the disease outcome. The structural changes in the genome, transcriptome, and proteome of SARS-CoV-2 promote the emergence of new variants of the virus and can reduce its interaction with antibodies and result in avoiding the neutralization. There is a strong correlation between the number of virus-specific CD4 T cells and neutralizing IgG antibody titers against SARS-CoV-2. During the primary viral infection, there is a wide variation in the cellular and humoral immune responses, patients with severe and prolonged symptoms showing highly imbalanced cellular and humoral immune responses. This review focuses on the generation and clinical significance of cellular immunity in the protection against severe acute infection and reinfection, as well as the potential involvement of seasonal coronavirus-specific cross-reactive T cells in response to SARS-CoV-2. covid-19 sars-cov-2 coronavirus cellular immunity immunological memory neutralizing antibodies cross-reactive immunity Medicine R Dmitry A. Vologzhanin verfasserin aut Aleksandr S. Golota verfasserin aut Tatyana A. Kamilova verfasserin aut Stanislav V. Makarenko verfasserin aut In Клиническая практика Eco-vector, 2020 13(2022), 2, Seite 66-87 (DE-627)DOAJ078636620 26188627 nnns volume:13 year:2022 number:2 pages:66-87 https://doi.org/10.17816/clinpract106239 kostenfrei https://doaj.org/article/39ba1e87f8294120b3e9075132952fc1 kostenfrei https://journals.eco-vector.com/clinpractice/article/viewFile/106239/pdf kostenfrei https://doaj.org/toc/2220-3095 Journal toc kostenfrei https://doaj.org/toc/2618-8627 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 13 2022 2 66-87 |
| allfields_unstemmed |
10.17816/clinpract106239 doi (DE-627)DOAJ039825175 (DE-599)DOAJ39ba1e87f8294120b3e9075132952fc1 DE-627 ger DE-627 rakwb rus Sergey G. Sсherbak verfasserin aut Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell response that forms a basis for an effective neutralizing antibody response. T cell responses develop early and correlate with the protection, but they are relatively attenuated in the severe disease, in part due to lymphopenia. Understanding the role of different T cell subpopulations in the protection or the COVID-19 pathogenesis is critical to the prevention and treatment. The expression profile of different T cell subpopulations varies with the COVID-19 severity and is associated with the degree of T cell responses and the disease outcome. The structural changes in the genome, transcriptome, and proteome of SARS-CoV-2 promote the emergence of new variants of the virus and can reduce its interaction with antibodies and result in avoiding the neutralization. There is a strong correlation between the number of virus-specific CD4 T cells and neutralizing IgG antibody titers against SARS-CoV-2. During the primary viral infection, there is a wide variation in the cellular and humoral immune responses, patients with severe and prolonged symptoms showing highly imbalanced cellular and humoral immune responses. This review focuses on the generation and clinical significance of cellular immunity in the protection against severe acute infection and reinfection, as well as the potential involvement of seasonal coronavirus-specific cross-reactive T cells in response to SARS-CoV-2. covid-19 sars-cov-2 coronavirus cellular immunity immunological memory neutralizing antibodies cross-reactive immunity Medicine R Dmitry A. Vologzhanin verfasserin aut Aleksandr S. Golota verfasserin aut Tatyana A. Kamilova verfasserin aut Stanislav V. Makarenko verfasserin aut In Клиническая практика Eco-vector, 2020 13(2022), 2, Seite 66-87 (DE-627)DOAJ078636620 26188627 nnns volume:13 year:2022 number:2 pages:66-87 https://doi.org/10.17816/clinpract106239 kostenfrei https://doaj.org/article/39ba1e87f8294120b3e9075132952fc1 kostenfrei https://journals.eco-vector.com/clinpractice/article/viewFile/106239/pdf kostenfrei https://doaj.org/toc/2220-3095 Journal toc kostenfrei https://doaj.org/toc/2618-8627 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 13 2022 2 66-87 |
| allfieldsGer |
10.17816/clinpract106239 doi (DE-627)DOAJ039825175 (DE-599)DOAJ39ba1e87f8294120b3e9075132952fc1 DE-627 ger DE-627 rakwb rus Sergey G. Sсherbak verfasserin aut Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell response that forms a basis for an effective neutralizing antibody response. T cell responses develop early and correlate with the protection, but they are relatively attenuated in the severe disease, in part due to lymphopenia. Understanding the role of different T cell subpopulations in the protection or the COVID-19 pathogenesis is critical to the prevention and treatment. The expression profile of different T cell subpopulations varies with the COVID-19 severity and is associated with the degree of T cell responses and the disease outcome. The structural changes in the genome, transcriptome, and proteome of SARS-CoV-2 promote the emergence of new variants of the virus and can reduce its interaction with antibodies and result in avoiding the neutralization. There is a strong correlation between the number of virus-specific CD4 T cells and neutralizing IgG antibody titers against SARS-CoV-2. During the primary viral infection, there is a wide variation in the cellular and humoral immune responses, patients with severe and prolonged symptoms showing highly imbalanced cellular and humoral immune responses. This review focuses on the generation and clinical significance of cellular immunity in the protection against severe acute infection and reinfection, as well as the potential involvement of seasonal coronavirus-specific cross-reactive T cells in response to SARS-CoV-2. covid-19 sars-cov-2 coronavirus cellular immunity immunological memory neutralizing antibodies cross-reactive immunity Medicine R Dmitry A. Vologzhanin verfasserin aut Aleksandr S. Golota verfasserin aut Tatyana A. Kamilova verfasserin aut Stanislav V. Makarenko verfasserin aut In Клиническая практика Eco-vector, 2020 13(2022), 2, Seite 66-87 (DE-627)DOAJ078636620 26188627 nnns volume:13 year:2022 number:2 pages:66-87 https://doi.org/10.17816/clinpract106239 kostenfrei https://doaj.org/article/39ba1e87f8294120b3e9075132952fc1 kostenfrei https://journals.eco-vector.com/clinpractice/article/viewFile/106239/pdf kostenfrei https://doaj.org/toc/2220-3095 Journal toc kostenfrei https://doaj.org/toc/2618-8627 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 13 2022 2 66-87 |
| allfieldsSound |
10.17816/clinpract106239 doi (DE-627)DOAJ039825175 (DE-599)DOAJ39ba1e87f8294120b3e9075132952fc1 DE-627 ger DE-627 rakwb rus Sergey G. Sсherbak verfasserin aut Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell response that forms a basis for an effective neutralizing antibody response. T cell responses develop early and correlate with the protection, but they are relatively attenuated in the severe disease, in part due to lymphopenia. Understanding the role of different T cell subpopulations in the protection or the COVID-19 pathogenesis is critical to the prevention and treatment. The expression profile of different T cell subpopulations varies with the COVID-19 severity and is associated with the degree of T cell responses and the disease outcome. The structural changes in the genome, transcriptome, and proteome of SARS-CoV-2 promote the emergence of new variants of the virus and can reduce its interaction with antibodies and result in avoiding the neutralization. There is a strong correlation between the number of virus-specific CD4 T cells and neutralizing IgG antibody titers against SARS-CoV-2. During the primary viral infection, there is a wide variation in the cellular and humoral immune responses, patients with severe and prolonged symptoms showing highly imbalanced cellular and humoral immune responses. This review focuses on the generation and clinical significance of cellular immunity in the protection against severe acute infection and reinfection, as well as the potential involvement of seasonal coronavirus-specific cross-reactive T cells in response to SARS-CoV-2. covid-19 sars-cov-2 coronavirus cellular immunity immunological memory neutralizing antibodies cross-reactive immunity Medicine R Dmitry A. Vologzhanin verfasserin aut Aleksandr S. Golota verfasserin aut Tatyana A. Kamilova verfasserin aut Stanislav V. Makarenko verfasserin aut In Клиническая практика Eco-vector, 2020 13(2022), 2, Seite 66-87 (DE-627)DOAJ078636620 26188627 nnns volume:13 year:2022 number:2 pages:66-87 https://doi.org/10.17816/clinpract106239 kostenfrei https://doaj.org/article/39ba1e87f8294120b3e9075132952fc1 kostenfrei https://journals.eco-vector.com/clinpractice/article/viewFile/106239/pdf kostenfrei https://doaj.org/toc/2220-3095 Journal toc kostenfrei https://doaj.org/toc/2618-8627 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 13 2022 2 66-87 |
| language |
Russian |
| source |
In Клиническая практика 13(2022), 2, Seite 66-87 volume:13 year:2022 number:2 pages:66-87 |
| sourceStr |
In Клиническая практика 13(2022), 2, Seite 66-87 volume:13 year:2022 number:2 pages:66-87 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
covid-19 sars-cov-2 coronavirus cellular immunity immunological memory neutralizing antibodies cross-reactive immunity Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Клиническая практика |
| authorswithroles_txt_mv |
Sergey G. Sсherbak @@aut@@ Dmitry A. Vologzhanin @@aut@@ Aleksandr S. Golota @@aut@@ Tatyana A. Kamilova @@aut@@ Stanislav V. Makarenko @@aut@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
DOAJ078636620 |
| id |
DOAJ039825175 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ039825175</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308032742.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17816/clinpract106239</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ039825175</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ39ba1e87f8294120b3e9075132952fc1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sergey G. Sсherbak</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell response that forms a basis for an effective neutralizing antibody response. T cell responses develop early and correlate with the protection, but they are relatively attenuated in the severe disease, in part due to lymphopenia. Understanding the role of different T cell subpopulations in the protection or the COVID-19 pathogenesis is critical to the prevention and treatment. The expression profile of different T cell subpopulations varies with the COVID-19 severity and is associated with the degree of T cell responses and the disease outcome. The structural changes in the genome, transcriptome, and proteome of SARS-CoV-2 promote the emergence of new variants of the virus and can reduce its interaction with antibodies and result in avoiding the neutralization. There is a strong correlation between the number of virus-specific CD4 T cells and neutralizing IgG antibody titers against SARS-CoV-2. During the primary viral infection, there is a wide variation in the cellular and humoral immune responses, patients with severe and prolonged symptoms showing highly imbalanced cellular and humoral immune responses. This review focuses on the generation and clinical significance of cellular immunity in the protection against severe acute infection and reinfection, as well as the potential involvement of seasonal coronavirus-specific cross-reactive T cells in response to SARS-CoV-2.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">covid-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sars-cov-2 coronavirus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cellular immunity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunological memory</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">neutralizing antibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cross-reactive immunity</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dmitry A. Vologzhanin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aleksandr S. Golota</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tatyana A. Kamilova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stanislav V. Makarenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Клиническая практика</subfield><subfield code="d">Eco-vector, 2020</subfield><subfield code="g">13(2022), 2, Seite 66-87</subfield><subfield code="w">(DE-627)DOAJ078636620</subfield><subfield code="x">26188627</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:66-87</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17816/clinpract106239</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/39ba1e87f8294120b3e9075132952fc1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://journals.eco-vector.com/clinpractice/article/viewFile/106239/pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2220-3095</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-8627</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">66-87</subfield></datafield></record></collection>
|
| author |
Sergey G. Sсherbak |
| spellingShingle |
Sergey G. Sсherbak misc covid-19 misc sars-cov-2 coronavirus misc cellular immunity misc immunological memory misc neutralizing antibodies misc cross-reactive immunity misc Medicine misc R Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications |
| authorStr |
Sergey G. Sсherbak |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)DOAJ078636620 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
26188627 |
| topic_title |
Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications covid-19 sars-cov-2 coronavirus cellular immunity immunological memory neutralizing antibodies cross-reactive immunity |
| topic |
misc covid-19 misc sars-cov-2 coronavirus misc cellular immunity misc immunological memory misc neutralizing antibodies misc cross-reactive immunity misc Medicine misc R |
| topic_unstemmed |
misc covid-19 misc sars-cov-2 coronavirus misc cellular immunity misc immunological memory misc neutralizing antibodies misc cross-reactive immunity misc Medicine misc R |
| topic_browse |
misc covid-19 misc sars-cov-2 coronavirus misc cellular immunity misc immunological memory misc neutralizing antibodies misc cross-reactive immunity misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Клиническая практика |
| hierarchy_parent_id |
DOAJ078636620 |
| hierarchy_top_title |
Клиническая практика |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)DOAJ078636620 |
| title |
Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications |
| ctrlnum |
(DE-627)DOAJ039825175 (DE-599)DOAJ39ba1e87f8294120b3e9075132952fc1 |
| title_full |
Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications |
| author_sort |
Sergey G. Sсherbak |
| journal |
Клиническая практика |
| journalStr |
Клиническая практика |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| container_start_page |
66 |
| author_browse |
Sergey G. Sсherbak Dmitry A. Vologzhanin Aleksandr S. Golota Tatyana A. Kamilova Stanislav V. Makarenko |
| container_volume |
13 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sergey G. Sсherbak |
| doi_str_mv |
10.17816/clinpract106239 |
| author2-role |
verfasserin |
| title_sort |
cellular immunity in patients with covid-19: molecular biology, pathophysiology, and clinical implications |
| title_auth |
Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications |
| abstract |
The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell response that forms a basis for an effective neutralizing antibody response. T cell responses develop early and correlate with the protection, but they are relatively attenuated in the severe disease, in part due to lymphopenia. Understanding the role of different T cell subpopulations in the protection or the COVID-19 pathogenesis is critical to the prevention and treatment. The expression profile of different T cell subpopulations varies with the COVID-19 severity and is associated with the degree of T cell responses and the disease outcome. The structural changes in the genome, transcriptome, and proteome of SARS-CoV-2 promote the emergence of new variants of the virus and can reduce its interaction with antibodies and result in avoiding the neutralization. There is a strong correlation between the number of virus-specific CD4 T cells and neutralizing IgG antibody titers against SARS-CoV-2. During the primary viral infection, there is a wide variation in the cellular and humoral immune responses, patients with severe and prolonged symptoms showing highly imbalanced cellular and humoral immune responses. This review focuses on the generation and clinical significance of cellular immunity in the protection against severe acute infection and reinfection, as well as the potential involvement of seasonal coronavirus-specific cross-reactive T cells in response to SARS-CoV-2. |
| abstractGer |
The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell response that forms a basis for an effective neutralizing antibody response. T cell responses develop early and correlate with the protection, but they are relatively attenuated in the severe disease, in part due to lymphopenia. Understanding the role of different T cell subpopulations in the protection or the COVID-19 pathogenesis is critical to the prevention and treatment. The expression profile of different T cell subpopulations varies with the COVID-19 severity and is associated with the degree of T cell responses and the disease outcome. The structural changes in the genome, transcriptome, and proteome of SARS-CoV-2 promote the emergence of new variants of the virus and can reduce its interaction with antibodies and result in avoiding the neutralization. There is a strong correlation between the number of virus-specific CD4 T cells and neutralizing IgG antibody titers against SARS-CoV-2. During the primary viral infection, there is a wide variation in the cellular and humoral immune responses, patients with severe and prolonged symptoms showing highly imbalanced cellular and humoral immune responses. This review focuses on the generation and clinical significance of cellular immunity in the protection against severe acute infection and reinfection, as well as the potential involvement of seasonal coronavirus-specific cross-reactive T cells in response to SARS-CoV-2. |
| abstract_unstemmed |
The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell response that forms a basis for an effective neutralizing antibody response. T cell responses develop early and correlate with the protection, but they are relatively attenuated in the severe disease, in part due to lymphopenia. Understanding the role of different T cell subpopulations in the protection or the COVID-19 pathogenesis is critical to the prevention and treatment. The expression profile of different T cell subpopulations varies with the COVID-19 severity and is associated with the degree of T cell responses and the disease outcome. The structural changes in the genome, transcriptome, and proteome of SARS-CoV-2 promote the emergence of new variants of the virus and can reduce its interaction with antibodies and result in avoiding the neutralization. There is a strong correlation between the number of virus-specific CD4 T cells and neutralizing IgG antibody titers against SARS-CoV-2. During the primary viral infection, there is a wide variation in the cellular and humoral immune responses, patients with severe and prolonged symptoms showing highly imbalanced cellular and humoral immune responses. This review focuses on the generation and clinical significance of cellular immunity in the protection against severe acute infection and reinfection, as well as the potential involvement of seasonal coronavirus-specific cross-reactive T cells in response to SARS-CoV-2. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
2 |
| title_short |
Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications |
| url |
https://doi.org/10.17816/clinpract106239 https://doaj.org/article/39ba1e87f8294120b3e9075132952fc1 https://journals.eco-vector.com/clinpractice/article/viewFile/106239/pdf https://doaj.org/toc/2220-3095 https://doaj.org/toc/2618-8627 |
| remote_bool |
true |
| author2 |
Dmitry A. Vologzhanin Aleksandr S. Golota Tatyana A. Kamilova Stanislav V. Makarenko |
| author2Str |
Dmitry A. Vologzhanin Aleksandr S. Golota Tatyana A. Kamilova Stanislav V. Makarenko |
| ppnlink |
DOAJ078636620 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.17816/clinpract106239 |
| up_date |
2024-07-04T00:53:31.488Z |
| _version_ |
1803607774581489666 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ039825175</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308032742.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17816/clinpract106239</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ039825175</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ39ba1e87f8294120b3e9075132952fc1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sergey G. Sсherbak</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. From the viewpoint of factors critical to contain the virus, the neutralizing antibodies to SARS-CoV-2 garner most of the attention, however, it is essential to acknowledge that it is the level of the virus-specific T cell and B cell response that forms a basis for an effective neutralizing antibody response. T cell responses develop early and correlate with the protection, but they are relatively attenuated in the severe disease, in part due to lymphopenia. Understanding the role of different T cell subpopulations in the protection or the COVID-19 pathogenesis is critical to the prevention and treatment. The expression profile of different T cell subpopulations varies with the COVID-19 severity and is associated with the degree of T cell responses and the disease outcome. The structural changes in the genome, transcriptome, and proteome of SARS-CoV-2 promote the emergence of new variants of the virus and can reduce its interaction with antibodies and result in avoiding the neutralization. There is a strong correlation between the number of virus-specific CD4 T cells and neutralizing IgG antibody titers against SARS-CoV-2. During the primary viral infection, there is a wide variation in the cellular and humoral immune responses, patients with severe and prolonged symptoms showing highly imbalanced cellular and humoral immune responses. This review focuses on the generation and clinical significance of cellular immunity in the protection against severe acute infection and reinfection, as well as the potential involvement of seasonal coronavirus-specific cross-reactive T cells in response to SARS-CoV-2.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">covid-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sars-cov-2 coronavirus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cellular immunity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunological memory</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">neutralizing antibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cross-reactive immunity</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dmitry A. Vologzhanin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aleksandr S. Golota</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tatyana A. Kamilova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stanislav V. Makarenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Клиническая практика</subfield><subfield code="d">Eco-vector, 2020</subfield><subfield code="g">13(2022), 2, Seite 66-87</subfield><subfield code="w">(DE-627)DOAJ078636620</subfield><subfield code="x">26188627</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:66-87</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17816/clinpract106239</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/39ba1e87f8294120b3e9075132952fc1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://journals.eco-vector.com/clinpractice/article/viewFile/106239/pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2220-3095</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-8627</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">66-87</subfield></datafield></record></collection>
|
| score |
7.3964148 |